Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over - Paridaens, R; Biganzoli, L; Bruning, P (J Clin Oncol, 2000)
, et al.